AbbVie Corporation v. Jamp Pharma Corporation

JurisdictionFederal Jurisdiction (Canada)
Citation2023 FC 1520
Date04 December 2023
CourtFederal Court (Canada)

Get this document and AI-powered insights with a free trial of vLex and Vincent AI

Get Started for Free

Unlock full access with a free 7-day trial

Transform your legal research with vLex

  • Complete access to the largest collection of common law case law on one platform

  • Generate AI case summaries that instantly highlight key legal issues

  • Advanced search capabilities with precise filtering and sorting options

  • Comprehensive legal content with documents across 100+ jurisdictions

  • Trusted by 2 million professionals including top global firms

  • Access AI-Powered Research with Vincent AI: Natural language queries with verified citations

vLex

Unlock full access with a free 7-day trial

Transform your legal research with vLex

  • Complete access to the largest collection of common law case law on one platform

  • Generate AI case summaries that instantly highlight key legal issues

  • Advanced search capabilities with precise filtering and sorting options

  • Comprehensive legal content with documents across 100+ jurisdictions

  • Trusted by 2 million professionals including top global firms

  • Access AI-Powered Research with Vincent AI: Natural language queries with verified citations

vLex

Unlock full access with a free 7-day trial

Transform your legal research with vLex

  • Complete access to the largest collection of common law case law on one platform

  • Generate AI case summaries that instantly highlight key legal issues

  • Advanced search capabilities with precise filtering and sorting options

  • Comprehensive legal content with documents across 100+ jurisdictions

  • Trusted by 2 million professionals including top global firms

  • Access AI-Powered Research with Vincent AI: Natural language queries with verified citations

vLex

Unlock full access with a free 7-day trial

Transform your legal research with vLex

  • Complete access to the largest collection of common law case law on one platform

  • Generate AI case summaries that instantly highlight key legal issues

  • Advanced search capabilities with precise filtering and sorting options

  • Comprehensive legal content with documents across 100+ jurisdictions

  • Trusted by 2 million professionals including top global firms

  • Access AI-Powered Research with Vincent AI: Natural language queries with verified citations

vLex

Unlock full access with a free 7-day trial

Transform your legal research with vLex

  • Complete access to the largest collection of common law case law on one platform

  • Generate AI case summaries that instantly highlight key legal issues

  • Advanced search capabilities with precise filtering and sorting options

  • Comprehensive legal content with documents across 100+ jurisdictions

  • Trusted by 2 million professionals including top global firms

  • Access AI-Powered Research with Vincent AI: Natural language queries with verified citations

vLex

Unlock full access with a free 7-day trial

Transform your legal research with vLex

  • Complete access to the largest collection of common law case law on one platform

  • Generate AI case summaries that instantly highlight key legal issues

  • Advanced search capabilities with precise filtering and sorting options

  • Comprehensive legal content with documents across 100+ jurisdictions

  • Trusted by 2 million professionals including top global firms

  • Access AI-Powered Research with Vincent AI: Natural language queries with verified citations

vLex
5 practice notes
  • 2023 Year In Review: Life Sciences In Canada
    • Canada
    • Mondaq Canada
    • January 25, 2024
    ...studies data. Find a full summary of Allergan v Juno here. AbbVie Corporation and Abbvie Biotechnology Ltd v JAMP Pharma Corporation, 2023 FC 1520 In a lengthy decision, the Federal Court invalidated AbbVie's CA2,504,868 (868 patent) and CA2,801,917 (917 Patent) patents for obviousness, but......
  • Federal Court Clarifies Validity And Evidence-Related Legal Principles, And Declines To Grant Injunction For Infringed Patent In Humira Decision
    • Canada
    • Mondaq Canada
    • January 25, 2024
    ...key points from the Federal Court's lengthy decision in AbbVie Corporation and Abbvie Biotechnology Ltd v JAMP Pharma Corporation, 2023 FC 1520 JAMP Pharma Corporation's ("JAMP")'s SIMLANDI biosimilar relates to AbbVie Corporation and Abbvie Biotechnology's ("AbbVie") HUMIRA biologic, the m......
  • Federal Court Declines To Grant Injunction For Infringement Of HUMIRA Formulation Patent
    • Canada
    • Mondaq Canada
    • January 2, 2024
    ...regimens and formulations of adalimumab (AbbVie's HUMIRA) and JAMP's biosimilar, SIMLANDI: AbbVie Corporation v Jamp Pharma Corporation, 2023 FC 1520. At issue were Canadian Patent 2,504,868 (868 patent): adalimumab dosing regimens for treating inflammatory bowel disease (IBD) (including Cr......
  • Canadian Patent Law In Review 2023: Notable Cases And Trends For 2024
    • Canada
    • Mondaq Canada
    • January 30, 2024
    ...Label": Apotex Inc. v. Janssen Inc., 2023 FCA 220 Infringement Without an Injunction: AbbVie Corporation v. JAMP Pharma Corporation, 2023 FC 1520 PMPRB Announces Next Steps in Guidelines Consultation Process Import, Export, and Possession as Infringement: Deeproot Green Infrastructure, LLC ......
  • Get Started for Free
5 firm's commentaries
  • 2023 Year In Review: Life Sciences In Canada
    • Canada
    • Mondaq Canada
    • January 25, 2024
    ...studies data. Find a full summary of Allergan v Juno here. AbbVie Corporation and Abbvie Biotechnology Ltd v JAMP Pharma Corporation, 2023 FC 1520 In a lengthy decision, the Federal Court invalidated AbbVie's CA2,504,868 (868 patent) and CA2,801,917 (917 Patent) patents for obviousness, but......
  • Federal Court Clarifies Validity And Evidence-Related Legal Principles, And Declines To Grant Injunction For Infringed Patent In Humira Decision
    • Canada
    • Mondaq Canada
    • January 25, 2024
    ...key points from the Federal Court's lengthy decision in AbbVie Corporation and Abbvie Biotechnology Ltd v JAMP Pharma Corporation, 2023 FC 1520 JAMP Pharma Corporation's ("JAMP")'s SIMLANDI biosimilar relates to AbbVie Corporation and Abbvie Biotechnology's ("AbbVie") HUMIRA biologic, the m......
  • Federal Court Declines To Grant Injunction For Infringement Of HUMIRA Formulation Patent
    • Canada
    • Mondaq Canada
    • January 2, 2024
    ...regimens and formulations of adalimumab (AbbVie's HUMIRA) and JAMP's biosimilar, SIMLANDI: AbbVie Corporation v Jamp Pharma Corporation, 2023 FC 1520. At issue were Canadian Patent 2,504,868 (868 patent): adalimumab dosing regimens for treating inflammatory bowel disease (IBD) (including Cr......
  • Canadian Patent Law In Review 2023: Notable Cases And Trends For 2024
    • Canada
    • Mondaq Canada
    • January 30, 2024
    ...Label": Apotex Inc. v. Janssen Inc., 2023 FCA 220 Infringement Without an Injunction: AbbVie Corporation v. JAMP Pharma Corporation, 2023 FC 1520 PMPRB Announces Next Steps in Guidelines Consultation Process Import, Export, and Possession as Infringement: Deeproot Green Infrastructure, LLC ......
  • Get Started for Free